Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The goal of this infrastructure protocol is to build and maintain a large and diverse
observational cohort study to support broad and cutting-edge research focused on NHL
prognosis and survivorship. The LEO cohort will promote identification of clinical (including
co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic,
tumor, and treatment factors that impact multiple outcomes (including event-free, overall and
lymphoma-specific survival; new onset comorbidities; and patient-reported outcomes). This
resource also will allow examination of the interaction among these factors in order to
better understand the clinical and molecular epidemiology of outcomes in NHL. Ultimately,
this approach will drive discovery and validation of treatment endpoints, improve
prognostication, and identify novel approaches to improve short and long-term outcomes for
NHL patients.
Phase
N/A
Funding Agency/Sponsor
Externally Peer-Reviewed
Disease
Lymphoma
Enrollment Eligibility
Inclusion Criteria:
- Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment
- Patients may have been treated as long as initial NHL diagnosis is within 6 months of
enrollment
- 18 years of age or older
Exclusion Criteria:
- Lymphoma diagnosis greater than 184 days from date of consent